Indiana biosciences research institute diabetes center, Pharmaceutical company

A team of researchers led by the Indiana Biosciences Research Institute Diabetes Center's Scientific Director Decio L. Eizirik, MD, PhD, has found that identifying new treatments for autoimmune diseases requires studying together the immune system AND target tissues.This study, "Gene expression signatures of target tissues in type 1 diabetes, lupus erythematosus, multiple sclerosis, and rheumatoid arthritis," is featured in the edition of Science Advances."We must move away from the present "immune-centric-only" view of autoimmune diseases. Indeed, trying to understand these diseases focusing on the immune system only, and forgetting the target tissues, maybe similar to attempting to fly a plane with only one wing," said Eizirik.Autoimmune diseases, which affect up to 5 percent of the population in different regions, suffer from a case of mistaken identity. The immune system is supposed to protect us from infectious diseases or tumors. Yet, during autoimmune diseases, the immune system mistakenly attacks and destroys components of our body, which then causes, for example, type 1 diabetes (T1D), systemic lupus erythematosus (SLE), multiple sclerosis (MS), or rheumatoid arthritis (RA).These four autoimmune diseases share almost half of the same genetic risks, chronic local inflammation, and mechsms leading to target tissue damage.Despite these common features, autoimmune disorders are traditionally studied independently and with a focus on the immune system rather than on the target tissues.Knowing that there is increasing evidence that the target tissues of these diseases are not innocent bystanders of the immune system attack, but instead are active participants, Eizirik and his team hypothesized that key inflammation-induced mechsms, potentially shared between T1D, SLE, MS and RA, may drive similar molecular signatures at the target tissue level."This research is significant in reaching the JDRF's mission to cure, treat and prevent T1D. Discovering the common pathways of tissue destruction across multiple autoimmune diseases will dramatically accelerate our path to a cure for T1D," said Frank Martin, Ph.D., JDRF director of research."Drugs that are effective in one autoimmune disease could be equally beneficial for another and quickly repurposed to make a big impact on people living with that disease. Characterizing the similarities and differences between multiple autoimmune diseases has the potential to transform the way we treat and cure these diseases in the future," added Martin.To test this hypothesis, the research team obtained gene expression data from diseased tissue sampled from controls or individuals affected by T1D, SLE, MS, and RA. This indicated major common gene expression changes at the target tissues of the four autoimmune diseases evaluated. One candidate gene in common between the four diseases is TYK2, a protein that regulates interferon signaling.The team showed in its research that the use of TYK2 inhibitors - already in use for other autoimmune diseases - protect b-cells against immune-mediated damage. This finding reinforces the importance of studying the target tissue of autoimmune diseases, in dialogue with the immune system, to better understand the genetics and natural history of these devastating diseases and to identify novel therapies.( With inputs from ANI )Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Home

City

Latest News

Cricket

LT Premium

National

International

Maharashtra

Opinions

Chhatrapati Sambhajinagar

Nagpur

Entertainment

Photos

Business

Technology

Sports

Lifestyle

Social Viral

Lokmat Games

Health

Lok Sabha Election 2024

Heatwave In India

Mumbai Water Cut

Maharashtra Lok Sabha Election

IPL 2024

Salman Khan

Indiana Biosciences Research Institute Diabetes CenterFOLLOW

Indiana biosciences research institute diabetes center, Latest News

Business :Lilly signs pact with Natco to accelerate availability of baricitinib for Covid-19 patients

Eli Lilly and Company said on Monday it has issued an additional royalty-free, non-exclusive voluntary license to Natco Pharma, a local pharmaceutical manufacturer of generic medicines. ...

Business :Lilly signs pact with Natco to accelerate availability of baricitinib for Covid-19 patients

Eli Lilly and Company said on Monday it has issued an additional royalty-free, non-exclusive voluntary license to Natco Pharma, a local pharmaceutical manufacturer of generic medicines. ...

Business :Lilly signs 3 more pacts to accelerate availability of baricitinib for Covid-19 patients

Eli Lilly and Company said on Thursday it has issued additional royalty-free, non-exclusive voluntary licenses to Dr Reddy's Ltd, MSN Laboratories and Torrent Pharmaceuticals who will collaborate to accelerate and expand the availability of baricitin ...

National :Dr Reddy's enters into licensing agreement with Eli Lilly for COVID-19 treatment drug

Dr Reddy's Laboratories on Tuesday said that it has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company for the manufacture and commercialization of the drug baricitinib, in India. ...

Technology :New approach needed to study autoimmune diseases

A research team has recently determined that the "Immune only" focus of the current research must be updated to better understand autoimmune diseases such as type 1 diabetes and multiple sclerosis. ...

Health :A new approach to study autoimmune diseases

A team of researchers led by the Indiana Biosciences Research Institute Diabetes Center's Scientific Director Decio L. Eizirik, MD, PhD, has found that identifying new treatments for autoimmune diseases requires studying together the immune system AN ...